Risk & Policy Analysts (RPA), Verisk 3E, Mayer Brown, and FoBiG have been contracted by the European Commission (DG Employment, Social Affairs and Inclusion) to support a possible revision of the EU legal framework regulating occupational exposure to reprotoxic substances.  This framework comprises (amongst others) Directive 2004/37/EC (Carcinogens and Mutagens Directive, CMD) and Directive 98/24/EC (Chemical Agents Directive, CAD).

The stakeholder consultation exercise for this study is divided into two stages.  The aim of the first phase was to analyse current exposure to reprotoxic substances.  The purpose of the second (current) stage is to assess the impacts of policy options for changing the CAD and CMD.  An overview of the policy options considered in this study can be downloaded here. 

In addition to the policy options in the link above, we would be keen to hear your views on the Joint Declaration, recently published by Cefic, ECEG, ETUC and IndustriAll.

The second stage of consultation includes the following questionnaires:

• Questionnaire for national authorities (online survey, Word)
• Questionnaire for industry associations (online survey, Word)
• Questionnaire for companies (online survey, Word)
• Questionnaire for trade unions (online survey, Word)
• Questionnaire for OSH-practitioners and other stakeholder types (online survey, Word)

The Word version can be found under the 'Supporting Documentation' sidebar to the right hand side of this webpage.

Please complete the online survey or send the completed Word questionnaire to us by email.  The deadline for completing these questionnaires is the 23 November 2018.

If you need a German, Spanish, Polish or French translation of the questionnaire(s), please contact the study team.

The second stage of consultation for this study comprises questionnaires and telephone interviews.  The telephone interviews will serve the purpose of generating information for a more comprehensive assessment of the impacts of the policy options.  If you are interested in speaking to the study team, please indicate so in your response to the questionnaire or contact the study team by emailing reprotox@rpaltd.co.uk.

If you have any questions about the consultation or the study more generally, please contact reprotox@rpaltd.co.uk or +44 (0)1508 528 465.